The contract is for profiling of immunoglobulin E autoantibodies in serum.
Oncimmune, an autoantibody profiling company that provides research services to enable the delivery of precision medicine to the pharmaceutical and biotechnology industries, has announced a new agreement with a global pharmaceutical company.
Following a successful pilot project with a major pharmaceutical company, Oncimmune signed a contract with the same customer for a new larger project with a contract value of at least $1.5 million.
During the pilot project, Onsymune was able to demonstrate that its high-throughput bead-based platform can be used to reliably profile immunoglobulin E (IgE) autoantibodies in serum. The new project is expected to be completed within the next six months, with the majority of revenue expected to occur in fiscal year 2025.
Martin Gouldstone, CEO of Onsymune, said: “We are pleased that our scientific team has demonstrated that our high-throughput platform can be used to measure IgE, which is much more difficult to detect in serum than other immunoglobulins.”
Oncimmune is a precision medicine company specializing in the analysis of immune interactions through autoantibody profiling. Using an insight-generating platform approach, Oncimmune partners with pharmaceutical and biotechnology companies as well as contract research organizations (CROs) worldwide to discover novel biomarkers for the development of more targeted and effective treatments for a host of immune-mediated diseases.
Oncimmune is headquartered in the UK with discovery and development facilities in Dortmund, Germany.
